



個人經歷：

中文姓名：莊宏亨

英文姓名：Horng-Heng Juang

出生地：台北市

聯絡住址：桃園縣龜山鄉文化一路 259 號；長庚大學解剖科

聯絡電話：(03) 2118800 X5071

傳真機號碼：(03) 2118112

E-mail：hhj143@mail.cgu.edu.tw

學經歷：

長庚大學解剖科教授 (2012/ 8 -)

長庚大學解剖科副教授 (1996/8 – 2012/7)

長庚大學解剖科助理教授 (1994/10 – 1996/7)

馬里蘭大學巴爾的摩分校 (University of Maryland at Baltimore) 生理學博士

愛我華州立大學 (Iowa State University) 生殖生理學碩士

教授課程：大體解剖學、組織學、內分泌特論，書報討論，生物資訊分析

研究主題：

前列腺癌之發生率及致死率會因人種及區域而不同，雖然一般皆認為在亞洲之中國人得到前列腺癌之機率遠較西方人低。利用衛生署過去二十年來，台灣地區前列腺癌通報之資料作一對人種、地區、及年齡之統計分析，我們發現雖然前列腺癌之發生率及致死率在台灣地區與歐美國家比較仍相當低，但其之發生率及致死率卻逐年增加。在過去二十年內，台灣地區因前列腺癌致死之人口比率已增加一倍。此統計結果證實除了受老化人口急劇增加之因素外，應仍受其它未知因素(如微量離子,遺傳基因等)影響。膀胱癌是最常好發於泌尿道的癌症之一，在全世界統計曾指出膀胱癌亦是好發癌症總排名的第五位。根據台灣的

統計膀胱癌亦是第四位好發的泌尿道腫瘤。因為膀胱癌的症狀不太明顯，僅以血尿為主，因此膀胱癌的診斷不易，所以找尋一種敏感度及專一性高的診斷工具是我們極需努力的方向。故本實驗室主要是探討關於前列腺、癌膀胱癌與乳癌演變時之特定 oncogenes, tumor suppress genes, metastasis induce genes 之基因調控機制，利用 *in vitro* 細胞株與 *in vivo* 動物實驗來證實藥物與荷爾蒙在前列腺癌、膀胱癌與乳癌對特定基因之作用與細胞癌化演變所扮演之功能，並嘗試利用抗癌藥物或傳統中草藥來控前列腺癌、膀胱癌與乳癌之演變。

主要研究目標

1. 生殖生理 (Reproduction physiology)
2. 分子內分泌 (Molecular endocrinology)
3. 細胞代謝 (Cellular metabolism)
4. 基因調控 (Gene regulation)
5. 前列腺癌 (Prostate cancer)
6. 膀胱癌 (Bladder cancer)
7. 乳癌 (Breast cancer)

近年研究主題

1. 調控代謝之基因轉錄於前列腺
2. 微量離子對前列腺與膀胱癌之影響
3. 雄性素受體與甲狀腺素受體對前列腺之調控
4. 調控前列腺癌轉移之機制與探討膀胱癌之腫瘤標的基因
5. 維他命 D 對乳癌、肝癌、與膽道癌之機制
6. 探討口腔癌與鼻咽癌之致病因子

成果與著作：

1. **Juang HH**, Musah AI, Schwabe C, Anderson LL. 1989. Effect of relaxin and antirelaxin serum on porcine sperm motility. *Animal Reproduction Science* 20:21-29.
2. **Juang HH**, Musah AI, Schwabe C, Anderson LL. 1990. Immunoactive relaxin in boar seminal plasma and its correlation with sperm motility. *Animal Reproduction Science* 22:47-53.
3. **Juang HH**, Musah AI, Anderson LL. 1990. Ethylenediamine-tetracetic acid (EDTA) and caffeine are antagonistic to anti-relaxin serum inhibition of porcine sperm motility. *Animal Reproduction Science* 22:253-260.
4. Kapcala LP, **Juang HH**, Weng CF. 1990. Corticotropin-releasing hormone and dexamethasone do not alter secretion of immunoreactive- β -endorphin from dissociated fetal hypothalamic cell culture. *Brain Research* 532:76-81.

5. Kapcala LP, Weng CF, **Juang HH**. 1992. Protein kinase C activation stimulates beta-endorphin secretion from hypothalamic cells. *Brain Research Bulletin* 29:553-557.
6. **Juang HH**, Costello L, Franklin R. 1995. Androgen modulation of multiple start sites of the mitochondrial aspartate amino-transferase gene in rat prostate. *Journal of Biology Chemistry* 270:12629-12634.
7. Franklin R, **Juang HH**, Zou J, Costello L. 1995. Regulation of citrate metabolism by androgen in LNCaP human prostate carcinoma cell line. *Endocrine* 3:603-607.
8. **Juang HH**, Musah AI, Schwabe C, Ford, JJ, Anderson, LL. 1996. Relaxin in peripheral plasma of boars during development, coupling, after administration of human chorionic gonadotropin and after castration. *Journal of reproduction and Fertility* 107:1-6.
9. **Juang HH**. 2004. Modulation of mitochondrial aconitase on the bioenergy of human prostate carcinoma cells. *Molecular Genetics and Metabolism* 81:244-252.
10. **Juang HH**. 2004. Cyclic Adenosine 3',5'- Monophosphate mediate prolactin regulation of mitochondrial aconitase in human prostate carcinoma cells. *Molecular and Cellular Endocrinology* 219:141-149.
11. **Juang HH**. 2004. Nitroprusside stimulates mitochondrial aconitase gene expression through the cyclic adenosine 3',5'- monophosphate signal transduction pathway in human prostate carcinoma cells. *Prostate* 61:92-102.
12. **Juang HH**. 2004. Modulation of iron on mitochondrial aconitase expression in human prostatic carcinoma cells. *Molecular and Cellular Biochemistry* 265:185-194.
13. **Juang HH***, Hsieh ML, Tsui KH. 2004. Testosterone modulates mitochondrial aconitase in the full-length human androgen receptor-transfected PC-3 prostatic carcinoma cells. *Journal of Molecular Endocrinology* 33:121-132.
14. Tsui KH, Chang PL, Lin HT, **Juang HH***. 2004. Down-regulation of prostate specific antigen promoter by p53 in human prostate cancer cells. *Journal of Urology* 172:2035-2039.
15. Tsui KH, Wu LL, Chang PL, Hsieh ML, **Juang HH***. 2004. Identifying the combination of the transcriptional regulatory sequences on prostate-specific antigen and human glandular kallikrein genes. *Journal of Urology* 172:2029-2034.
16. Feng TH, Tsui KH, **Juang HH***. 2005. Cholesterol modulation of the expression of mitochondrial aconitase in human prostatic carcinoma cells. *Chinese Journal of Physiology* 48:93-100.
17. Hsieh ML, **Juang HH***. 2005. Cell growth effects of triiodothyronine and expression of thyroid hormone receptor in prostate carcinoma cells. *Journal of Andrology* 26: 422-428.

18. Tsui KH, Chang PL, **Juang HH***. 2006. Zinc blocks gene expression of mitochondrial aconitase in human prostatic carcinoma cells. *International Journal of Cancer* 118:609-615.
19. Tsui KH, Chang PL, **Juang HH***. 2006. Manganese antagonizes iron blocking the mitochondrial aconitase expression in human prostate carcinoma cells. *Asian Journal of Andrology* 8:307-315.
20. Tsui KH, Feng TH, Chang PL, **Juang HH***. 2007. Calcium deregulate mitochondrial aconitase gene in the human prostate carcinoma cells. *Andrology Update* 1:304-312.
21. Tsui KH, Chen SM, Wang TM, **Juang HH**, Cheng CL, Sun GH, Chang PL. 2007. Comparisons of voided urine cytology, nuclear matrix protein-22 and bladder tumor associated antigen tests for bladder cancer of geriatric male patients in Taiwan. *Asian Journal of Andrology* 9:711-715.
22. Tsiu KH, **Juang HH**, Lee TH, Chang PL, Che CL, Yuang B Y-M. 2008. Association of nucleophosmin/B23 with bladder cancer recurrence based on immunohistochemical assessment in clinical samples. *Acta Pharmacologica Sinica* 29:364-370.
23. Tsui KH, Hsieh WC, Lin MH, Chang PL, **Juang HH***. 2008. Triiodothyronine Modulates cell proliferation of human prostatic carcinoma cells by downregulation of the b-cell translocation gene 2. *Prostate* 68: 610-619.
24. Tsui KH, Feng TH, Chung LC, Chao CH, Chang PL, **Juang HH***. 2008. Prostate specific antigen gene expression in androgen insensitive prostate carcinoma subculture cell line. *AntiCancer Research* 28:1969-1976.
25. Tsui KH, Chang PL, Feng TH, Chung LC, Shu SY, **Juang HH***. 2008. Down-regulation of matrix metalloproteinase by overexpression of bikunin attenuates cell invasion in prostate carcinoma cells. *AntiCancer Research* 28:1977-1984.
26. Tsui KH, Chang PL, Feng TH, Chung LC, Sung HC, **Juang HH***. 2008. Evaluating the function of matrix metalloproteinase and N-acetylglucosaminyltransferase V in prostate cancer metastasis. *Anticancer Research* 28: 1993-2000.
27. Tsui KH, Feng TH, Hsieh WC, Chang PL, **Juang HH***. 2008. Expression of interleukin-6 is downregulated by 17-(allylamino)-17-demethoxygeldanamycin in human prostatic carcinoma cells. *Acta Pharmacologica Sinica* 29:1334-1341.
28. Tsui KH, Feng TH, Lin CM, Chang PL, **Juang HH***. 2008. Curcumin blocks the activating of androgen and interleukin-6 on prostate specific antigen expression in human prostatic carcinoma cells. *Journal of Andrology* 29: 661-668.
29. Pang ST, Hsieh WC, Chuang CK, Chao CH, Weng WH, **Juang HH***. 2009. Thioredoxin-interacting protein: an oxidative-stress related gene is upregulated by glucose in human prostate carcinoma cells. *Journal of Molecular Endocrinology*

42:205-214.

30. **Juang HH**, Lin YF, Chang PL, Tsui KH. 2010. Cardiac glycosides reduce prostate specific antigen expression by downregulation of prostate-derived Ets factor. *Journal of Urology* 84: 2158-2164.
31. Tsui KH, Feng TH, Lin YF, Chang PL, **Juang HH***. 2011. p53 downregulates the gene expression of mitochondrial aconitase in human prostate carcinoma cells. *Prostate* 71:62-70.
32. Tsui KH, Lin YF, Chen YH, Chang PL, **Juang HH***. 2011. Mechanisms by which interleukin-6 regulates prostate specific antigen gene expression in prostate LNCaP carcinoma cells. *Journal of Andrology* 32:383-393.
33. Chung LC, Tsui KH, Feng TH, Lee SL, Chang PL, **Juang HH***. 2011. Curcumin provides potential protection against the activation of hypoxia and prolyl 4-hydroxylase inhibitors on prostate-specific antigen expression in human prostate carcinoma cells. *Molecular Nutrition and Food Research* 55:1666-1676.
34. Chiang KC, Yeh CN, Chen HY, Lee JM, **Juang HH**, Chen MF, Takano M, Kittaka A, and Chen TC. 2011. 19-Nor-2 α -(3-hydroxypropyl)-1 α ,25-dihydroxyvitamin D3 (MART-10) is a potent cell growth regulator with enhanced chemotherapeutic potency in liver cancer cells. *Steroids* 76:1513-1519.
35. Chung LC, Tsui KH, Feng TH, Lee SL, Chang PL, **Juang HH***. 2012. L-Mimosine blocks cell proliferation via upregulation of B-cell translocation gene 2 and N-myc downstream regulated gene 1 in prostate carcinoma cells *American Journal of Physiology Cell Physiology* 302:C676-C685.
36. Tsui KH, Chung LC, Feng TH, Chang PL, **Juang HH***. 2012. Upregulation of prostate-derived ets factor by luteolin causes inhibition of cell proliferation and cell invasion in prostate carcinoma cells. *International Journal of Cancer* 130: 2812-2823.
37. Tsui KH, Chang YL, Feng TH, Chang PL, **Juang HH***. 2012. Glycoprotein transmembrane nmb: an androgen-downregulated gene attenuates cell invasion and tumorigenesis in prostate carcinoma cells. *Prostate* 72:1431-1442.
38. Tsui KH, Chang YL, Feng TH, Chung LC, Lee TY, Chang PL, **Juang HH***. 2012. Growth differentiation factor-15 upregulates interleukin-6 to promote tumorigenesis of prostate carcinoma PC-3 cells. *Journal of Molecular Endocrinology* 49:153-163.
39. Chiang KC, Yeh CN, Chen SC, Shen SC, Hsu JT, Yeh TS, Pang JH, Su LJ, Takano M, Kittaka A, **Juang HH***, Chen TC*. 2012. MART-10, a new generation of vitamin D analog, is more potent than 1 α ,25-dihydroxyvitamin D(3) in inhibiting cell proliferation and inducing apoptosis in ER+ MCF-7 breast cancer cells. *Evidence Based Complement Alternative Medicine* 2012:e310872.

40. Chiang KC, Yeh CN, Hsu JT, Yeh TS, Jan YY, Wu CT, Chen HY, Jwo SC, Takano M, Kittaka A, **Juang HH***, Chen TC.* 2013. Evaluation of the potential therapeutic role of a new generation of vitamin D analog, MART-10, in human pancreatic cancer cells in vitro and in vivo. *Cell Cycle* 12:1316-1325.
41. Tsui KH, Wang SW, Chung LC, Feng TH, Chen YH, Chang PL, **Juang HH***. 2013. Mechanisms by which interleukin-6 attenuates cell invasion and tumorigenesis in human bladder carcinoma cells. *BioMed Research International* 2013:e791212
42. Yeh CN, Chiang KC, **Juang HH**, Pang JH S, Yu CS, Lin KJ, Yeh TS*, Jan YY* 2013. Reappraisal of the therapeutic role of celecoxib in cholangiocarcinoma. *PLoS one* 8:e69928.
43. Tsui KH, Chung LC, Wang SW, Feng TH, Chang PL, **Juang HH***. 2013. Hypoxia upregulates the gene expression of mitochondrial aconitase in prostate carcinoma cells. *Journal of Molecular Endocrinology* 51:131-141
44. **Juang HH**, Chung LC, Feng TH, Lee YH, Chang PL, Tsui KH. 2013. Metallothionein 3: an androgen-upregulated gene enhances cell invasion and tumorigenesis of prostate carcinoma cells. *Prostate* 73:1495-1506.
45. Chiang KC, Yeh CN , Hsu JT , Chen LW , Kuo SF , Sun CC , Huang CC , Pang JHS , Flanagan JN , Takano M, Kittaka A, **Juang HH**, Yang SW*, Chen TC* . 2013. MART-10, a novel vitamin D analog, inhibits head and neck squamous carcinoma cells growth through cell cycle arrest at G0/G1 with upregulation of p21 and p27 and downregulation of telomerase. *Journal of Steroid Biochemistry and Molecular Biology* 138:427-434.
46. Lee WC, Lin YH, Hou CP, Chang PL, Chen CL, **Juang HH**, Tsui KH. 2013. Prostatectomy using different lasers for the treatment of benign prostate hyperplasia in aging males. *Clinical Interventions in Aging* 8: 1483–1488
47. Chiang KC, Chen SC, Yeh CN, Pang S JH , Shen SC, Hsu JT, Liu YY, Chen LW, Kuo SF, Takano M, Kittaka A, Sun CC, **Juang HH***, Chen TC*. 2014. MART-10, a less calcemic vitamin D analog, is more potent than 1 α , 25-dihydroxyvitamin D3 in inhibiting the metastatic potential of MCF-7 breast cancer cells in vitro. *Journal of Steroid Biochemistry and Molecular Biology* 139:54-60.
48. Chiang KC, Tsui KH, Chung LC, Yeh CN, Chang PL, Chen WT, **Juang HH***. 2014. Topoisomerase inhibitors modulate gene expression of B-cell translocation gene 2 and prostate specific antigen in prostate carcinoma cells. *PLoS One* 9:e89117.
49. Chiang KC, Tsui KH, Chung LC, Yeh CN, Chen WT, Chang PL, **Juang HH***. 2014. Celastrol blocks interleukin-6 gene expression via downregulation of NF- κ B in prostate carcinoma cells. *PLoS One* 9:e93151
50. Chiang KC, Yeh CN, Lin KJ, Su LJ, Yen TC, Pang JHS, Kittaka A, Sun CC, Chen

- MF, Jan YY, Chen TA, **Juang HH***, Yeh TS*. 2014. Chemopreventive and chemotherapeutic effect of dietary supplementation of vitamin D on cholangiocarcinoma in a chemical-induced animal model. *Oncotarget* 5:3849-3861.
51. Chiang KC, Tsui KH, Chung LC, Yeh CN, Feng TH, Chen WT, Chang PL, Chiang HY, **Juang HH***. 2014. Cisplatin modulates B-cell translocation gene 2 to attenuate cell proliferation of prostate carcinoma cells in both p53-dependent and p53-independent pathways. *Scientific Reports* 4:5511.
 52. Hou CP, Chen CL, Lin YH, Chang PL, **Juang HH**, Tsui KH*. 2014. Prostatic urethral angle might be a predictor of treatment efficacy of α -blockers in men with lower urinary tract symptoms. *Drug Design, Development and Therapy* 8:937-943.
 53. Yang PS, Hsu YC, Lin YH, Hou CP, Chen CL, Chang PL, **Juang HH**, Tsui KH*. 2014. The expression sequence tag is an effective method for screening DNA segments that predict urinary bladder transitional cell carcinoma prognosis. *OncoTargets and Therapy* 7:1777-1781.
 54. Shao IH, Lin YH, Hou CP, **Juang HH**, Chen CL, Chang PL, Tsui KH*. 2014. Risk factors associated with ineligibility of adjuvant cisplatin-based chemotherapy after nephroureterectomy. *Drug Design, Development and Therapy* 8: 1985–1991.
 55. Chiang KC, Yeh CN, Hsu JT, Jan YY, Chen LW, Kuo SF, Takano M, Kittaka Atsushi, Chen TC, Chen WT, Pang JHS, Yeh TS, **Juang HH***. 2014. The Vitamin D analog, MART-10, represses metastasis potential via downregulation of epithelial-mesenchymal transition in pancreatic cancer cell. *Cancer Letters* 354:235-244.
 56. Lee JC, Chung LC, Chen YJ, Feng TH, **Juang HH***. 2014. N-myc downstream-regulated gene 1 downregulates cell proliferation, invasiveness and tumorigenesis in human oral squamous cell carcinoma. *Cancer Letters* 355:242-252.
 57. Hou CP, Lee WC, Lin YH, Chen SM, Chen CL, Chang PL, **Juang HH**, Tsui KH*. 2015. Neoadjuvant hormone therapy following treatment with robotic-assisted radical prostatectomy achieved favorable in high-risk prostate cancer. *OncoTargets and therapy* 8:15-19.
 58. Chiang KC, Yeh CN, Chung LC, Feng TH, Sun CC, Chen MF, Jan YY, Chen SC, Yeh TS, **Juang HH***. 2015. WNT-1 inducible signaling pathway protein 1 enhances growth and tumorigenesis in human breast cancer. *Scientific Reports* 5:8686.
 59. Tsui KH, Chung LC, Feng TH, Lee TY, Chang PL, Chen WT, **Juang HH***. 2015. Divergent effect of liver X receptor agonists on prostate-specific antigen expression is dependent on androgen receptor in prostate carcinoma cells. *Prostate*

75:603-615.

60. Lee JC, Chung LC, Chen YJ, Feng TH, Chen WT, **Juang HH***. 2015. Upregulation of B-cell translocation gene 2 by epigallocatechin-3-gallate via p38 and ERK signaling blocks cell proliferation in human oral squamous cell carcinoma cells. *Cancer Letters* 360:310-318.
61. Tsui KH, Hsu SY, Chung LC, Lin YH, Feng TH, Lee TY, Chang PL, **Juang HH***. 2015. Growth differentiation factor-15: a p53- and demethylation-upregulating gene represses cell proliferation, invasion, and tumorigenesis in bladder carcinoma cells. *Scientific Reports* 5: 12870
62. Chiang KC, Yen CL, Yeh CN, Hsu JT, Chen LW, Kuo SF, Wang SY, Sun CC, Kittaka A, Chen TC, Yeh TS, Hsu SY, **Juang HH***. 2015. Hepatocellular carcinoma cells express 25(OH)D-1 α -hydroxylase and is able to convert 25(OH)D to 1 α ,25(OH)₂D, leading to the 25(OH)D-induced growth inhibition. *Journal of Steroid Biochemistry and Molecular Biology* 154: 47–52.
63. Chiang KC, Chen HY, Hsu SY, Pang JHS, Hsu JT, Yeh TS, Chen LW, Kuo SF, Chen SC, Sun CC, Yeh CN and **Juang HH***. 2015. PTEN insufficiency modulates ER+ breast cancer cell cycle progression and increases cell growth in vitro and in vivo. *Drug Design, Development and Therapy* 9: 4631–4638.
64. Chiang KC, Kuo SF, Chen CH, Ng S, Lin SF, Yeh CN, Chen LW, Takano M, Chen TC, **Juang HH**, Kittaka A, Lin JD and Pang JS. 2015. MART-10, the vitamin D analog, is a potent drug to inhibit anaplastic thyroid cancer cell metastatic potential. *Cancer Letters* 369:76-85.
65. Shen CR, **Juang HH**, Chen HS, Yang CJ, Wu CJ, Lee MH, Hwang YS, Kuo ML, Chen YS, Chen JK, Liu CL. 2015. The correlation between chitin and acidic mammalian chitinase in animal models of allergic asthma. *International Journal of Molecular Sciences* 16: 27371–27377.
66. Chiang KC, Sun CC, Chen MH, Huang CY, Hsu JT, Yeh TS, Chen LW, Kuo SF, **Juang HH***, Takano M, Kittaka A, Chen TC, Yeh CN*, Pang JHS* 2016. MART-10, the new brand of 1 α , 25 (OH) 2 D 3 analog, is a potent anti-angiogenic agent in vivo and in vitro. *Journal of Steroid Biochemistry and Molecular Biology*. 155: 26-34.
67. Tsui KH, Lin YH, Chung LC, Chuang ST, Feng TH, Chiang KC, Chang PL, Yen CL. **Juang HH***. 2016. Prostate-derived ets factor represses tumorigenesis and modulates epithelial-to-mesenchymal transition in bladder carcinoma cells. *Cancer Letters* 375:142-151.
68. Chiang KC, Yeh TS, Chen SCh, Pang JHS, Yeh CN, Hsu JT, Chen LW, Kuo SF, Takano M, Kittaka A, Chen TC, Sun CC, **Juang HH***. 2016. The Vitamin D analog, mart-10, attenuates triple negative breast cancer cells metastatic potential.

69. Yang SW, Tsai CY, Pan YC, Yeh CN, Pang JHS, Takano M, Kittaka A, **Juang HH**, Chen TC, Chiang KC. 2016. MART-10, a newly synthesized vitamin D analog, represses metastatic potential of head and neck squamous carcinoma cells. *Drug Design, Development and Therapy* 10:1995–2002
70. Chiang KC, Yeh CN; Pang JH, Hsu JT, Yeh TS, Chen LW, Kong SF, Hsieh P, Pan YC, Takano M, Chen TC, Kittaka A, Feng TH, **Juang HH***. 2016. $1\alpha,25(\text{OH})_2\text{D}_3$ analog, MART-10, inhibits neuroendocrine tumor cell growth through Induction of G0/G1 cell cycle arrest and apoptosis. *Anticancer Research* 36: 3307-3314
71. Chiang KC, Hsu SY, Lin SJ, Yeh CN, Pang JHS, Wang SY, Hsu JT, Yeh TS, Chen LW, Kuo SF, Cheng YC, **Juang HH***. 2016. PTEN insufficiency increases breast cancer cell metastasis in vitro and in vivo - in a xenograft zebrafish model. *Anticancer Research* 36: 3997-4005.
72. Chiang KC, Yeh CN, Huang CC, Yeh TS, Pang JHS, Hsu JT, Chen LW, Kuo SF, Kittaka A, Chen TC, **Juang HH***. 2016. $25(\text{OH})\text{D}$ is effective to repress human cholangiocarcinoma cell growth through the conversion of $25(\text{OH})\text{D}$ to $1\alpha,25(\text{OH})_2\text{D}_3$. *International Journal of Molecular Sciences* 17: 1326.
73. Lee JC, Chiang KC, Feng TH, Chen YJ, Chuang ST, Tsu KH, Chung LC, **Juang HH***. 2016. The iron chelator, Dp44mT, effectively inhibit human oral squamous cell carcinoma cell growth in vitro and in vivo. *International Journal of Molecular Sciences* 17:1435
74. Chiang KC, Yeh TS, Wu RC, Pang JHS, Cheng CT, Wang S, **Juang HH***, Yeh CN* 2016. Lipocalin 2 (LCN2) is a promising target for cholangiocarcinoma treatment and bile LCN2 level is a potential cholangiocarcinoma diagnostic marker. *Scientific Reports* 6:36138.
75. Chiang NY, Peng YM, **Juang HH**, Chen TC, Pan HL, Chang GW, Lin HH. 2017. GPR56/ADGRG1 activation promotes melanoma cell migration via NTF dissociation and CTF-mediated $\text{G}\alpha_{12/13}/\text{RhoA}$ signaling. *The Journal of Investigative Dermatology* 137: 727-736.
76. Chung LC, Chiang KC, Feng TH, Chang KS, Chuang ST, Chen YJ, Tsui KH, Lee JC, **Juang HH***. 2017. Caffeic acid phenethyl ester upregulates N-myc downstream regulated gene 1 via ERK pathway to inhibit human oral cancer cell growth in vitro and in vivo. *Molecular Nutrition and Food Research* 61:1600842
77. Chiang KC, Yeh TS, Huang CC, Chang YC, **Juang HH***, Cheng CT, Pang JHS, Hsu JT, Takano M, Chen TC, Kittake A*, Hsiao M, Yeh CN*. 2017. MART-10 represses cholangiocarcinoma cell growth and high vitamin D receptor expression indicates better prognosis for cholangiocarcinoma. *Scientific Reports*.7:43773

78. Lin YH, Hou CP, Chen TH, **Juang HH**, Chang PL, Yang PS, Lin YS, Chen CL, Tsui KH. 2017. Is Diabetes Mellitus associated with clinical outcome in aging male treated with transurethral resection of prostate for bladder outlet obstruction: Implications from Taiwan Nationwide Population-Based cohort study. *Clinical Interventions in Aging*. 12: 535–541.
79. Chiang KC, Yeh CN, Pang JHS, Hsu JT, Yeh TS, Chen LW, Kuo SF, Takano M, Chen TC, Kittaka A, Hsieh PJ, **Juang HH***. 2017. $1\alpha,25(\text{OH})_2\text{D}_3$ Analog, MART-10, inhibits neuroendocrine tumor cell metastasis after VEGF-A stimulation. *AntiCancer Research* 37: 6215-6221.
80. Tsui KH, Chang YL, Feng TH, Hou CP, Lin YH, Yang PS, Lee BW, **Juang HH***. 2018. Capillarisin blocks prostate-specific antigen expression on activation of androgen receptor in prostate carcinoma cells. *Prostate* 78:242-249.
81. Lin YH, Hou CP, Chen TH, **Juang HH**, Chang PL, Yang PS, Chen CL, Tsui KH. 2018. Transurethral resection of the prostate provides more favorable clinical outcomes compared with conservative medical treatment in patients with urinary retention caused by benign prostatic obstruction. *BMC Geriatrics* 18:15.
82. Chiang KC, Yeh CN, Yeh TS, **Juang HH**, Chen LW, Kuo SF, Chen MH, Chen TC, Takano M, Kittaka A, Pang JHS. 2018. MART-10, a $1\alpha, 25 (\text{OH}) 2\text{D}_3$ analog, potently represses metastasis of ER+ breast cancer cells with VEGF-A overexpression. *Anticancer research* 38: 3879-3887
83. Tsui KH, Chiang KC, Feng TH, Chang KS, Lin YH, **Juang HH***. 2018. BTG2 is a tumor suppressor gene and upregulated by p53 and PTEN in human bladder carcinoma cells. *Cancer Medicine* 7:184-195.
84. Tsui KH, Chang YL, Yang PS, Hou CP, Lin YH, Lee BW, Feng TH, **Juang HH***. 2018. The inhibitory effects of capillarisin on cell proliferation and invasion of prostate carcinoma cells. *Cell Proliferation* 51:e12429
85. Hou CP, Lin YH, Chen TH, Chang PL, **Juang HH**, Chen CL, Yang PS, Tsui KH. 2018. Transurethral resection of the prostate achieves favorable outcomes in stroke patients with symptomatic benign prostate hyperplasia. *The Aging man* 21: 9-16.
86. Chiang KC, Yang SW, Chang KP, Feng TH, Chang KS, Tsui KH, Shin YS, Chen CC, Chao M, **Juang HH***. 2018. Caffeic acid phenethyl ester induces N-myc downstream regulated gene 1 to inhibit cell proliferation and invasion of human nasopharyngeal cancer cells. *International Journal of Molecular Sciences*, 19: 1397.
87. Chen CW, Hu S, Tsui KH, Hwang GS, Chen ST, Tang TK, Cheng HT, Yu JW, Wang HC, **Juang HH**, Wang PS, Wang SW. 2018. Anti-inflammatory effects of gossypol on human lymphocytic jurkat cells via regulation of MAPK signaling and cell cycle. *Inflammation* 42: 2265–2274.

88. Chiang KC, Huang ST, Wu RC, Huang SC, Yeh TS, Chen MH, Hsu JT, Chen LW, Kuo SF, Chueh HY, **Juang HH**, Hung SI, Yeh CN, Pang JSH. 2019. Interferon α -inducible protein 27 is an oncogene and highly expressed in cholangiocarcinoma patients with poor survival. *Cancer Management and Research* 11: 1893–1905
89. Tsui KH, Hou CP, Chang KS, Lin YH, Feng TH, Chen CC, Shin YS, **Juang HH***. 2019. Metallothionein 3 is a hypoxia-upregulated oncogene enhancing cell invasion and tumorigenesis in human bladder carcinoma cells. *International Journal of Molecular Science*. 20: 980.
90. Chiang KC, Yeh CN, **Juang HH**, Yeh TS. 2019. Method of screening breast cancer by using serum WISP1 level as a biomarker. US Patent App. 15/857,870.
91. Lin YH, Hou CP, Juang HH, Chang PL, Chen TH, Chen CL, Tsui KH. 2019. Association between bladder outlet obstruction and bladder cancer in patients with aging male. *Journal of Clinical Medicine* 8, 1550
92. Chang KS, Tsui KH, Lin YH, Hou CP, Feng TH, **Juang HH*** 2019. Migration and invasion enhancer 1 is a NF- κ B-inducing gene enhancing cell proliferation and invasion ability of human prostate carcinoma cells *in vitro* and *in vivo*. *Cancers* 11:1486.
93. Tsui KH, Lin YH, Chang KS, Hou CP, Chen PJ, Feng TH, **Juang HH*** 2019. Transgelin, a p53- and PTEN-upregulated gene, inhibits cell proliferation and invasion of human bladder carcinoma cells *in vitro* and *in vivo*. *International Journal of Molecular Sciences* 20:4946.
94. Hsu CW, **Juang H⁺**, Kuo CY, Li HP, Iang SB, Lin SH, Yeh CT, Mei Chao M 2019. Structural pattern differences in unbranched rod-like RNA of hepatitis delta virus affect RNA editing. *Viruses* 11:934.
95. Chiang KC, Tsui KH, Lin YH, Hou CP, Chang KS, Tsai HH, Chen CC, Shin YS, Feng TH, **Juang HH***. 2020. Anti-oxidation and anti-apoptosis characteristics of heme oxygenase-1 enhances tumorigenesis of human prostate carcinoma cells. *Translational Oncology* 13:102-112.
96. Lin YH, Tsui KH, Chang KS, Hou CP, Chen PJ, Feng TH, **Juang HH***. 2020. Maspin is a PTEN-upregulated and p53-upregulated tumor suppressor gene and acts as an HDAC1 inhibitor in human bladder cancer. *Cancers* 12:10.
97. Chen YT, Ou Yang WT, **Juang HH**, Chen CL, Chen HW, Tsui KH, Chang YH, Tsai CH, Hsueh C, Liao WC. 2020. Proteomic characterization of arsenic and cadmium exposure in bladder cells. *Rapid Communications in Mass Spectrometry* 34:e8578.
98. Hou CP, Lin YH, Juang HH, Chang PL, Chen CL, Yang PS, Tsui KH. 2020. Clinical outcome of transurethral enucleation of the prostate using the 120-W

- thulium Laser (Vela™ XL) compared to bipolar transurethral resection of the prostate (TURP) in aging male. *Aging* 12:1888-1898.
99. Hou CP, Lin YH, Juang HH, Chang PL, Chen CL, Yang PS, Lee CC, Tsui KH. 2020. Effect of ureteral calculus in outpatients receiving semi-rigid ureteroscopy laser lithotripsy. *Medicine* 99:10
 100. Chiang KC, Chang KS, Hsu SY, Sung HC, Feng TH, Chao M, **Juang HH*** 2020. Human heme oxygenase-1 induced by interleukin-6 via JAK/STAT3 pathways is a tumor suppressor gene in hepatoma cells. *Antioxidants* 9:251.
 101. Tsui KH, Chang KS, Sung HC, Hsu SY, Lin YH, Hou CP, Yang PS, Chen, CL, Feng, TH, **Juang HH***. 2021. Mucosa-associated lymphoid tissue 1 is an oncogene inducing cell proliferation, invasion, and tumor growth via the upregulation of NF-κB activity in human prostate carcinoma cells. *Biomedicines* 9:250
 102. **Juang HH**, Chen SM, Lin G, Chiang MH, Hou CP, Lin YH, Yang PS, Chang PL, Chen CL, Lin KY, Tsui KH. 2021. The clinical experiences of urine metabolomics of genitourinary urothelial cancer in a tertiary hospital in Taiwan. *Frontiers in Oncology*. 11:680910.
 103. Ho CP, Tsui K-H, Chang KS, Sung HC, Hsu SY, Lin YH, Yang PS, Chen CL, Feng TH, **Juang HH*** 2021. Caffeic acid phenethyl ester inhibits the growth of bladder carcinoma cells by upregulating growth differentiation factor 15. *Biomedical Journal* doi.org/10.1016/j.bj.2021.10.006
 104. Chang KS, Tsui KH, Hsu SY, Sung HC, Lin YH, Hou CP, Yang PS, Chen CL, Feng TH, **Juang HH*** 2022. The antitumor effect of caffeic acid phenethyl ester by downregulating mucosa-associated lymphoid tissue 1 via AR/p53/NF-κB signaling in prostate carcinoma cells. *Cancers* 14: 27..
 105. Chen PY, Chen SM, **Juang HH**, Hou CP, Lin YH, Yang PS, Chen CL, Chang, PL, Lin KY, Tsui KH. 2022. Prostate-specific antigen velocity predicts surgical outcome of thulium laser enucleation of the prostate. *Frontiers in Medicine* 8: 783221.
 106. Hou CP, Lin YH, Yang PS, Chang PL, Chen CL, Lin KY, **Juang HH**, Weng SC, Tsui KH. 2022. Clinical outcome of endoscopic enucleation of the prostate compared with robotic-assisted simple prostatectomy for prostates larger than 80 cm³ in aging male. *American journal of men's health* 15: 15579883211064128
 107. Chen YT, Hou CP, **Juang HH**, Lin YH, Yang PS, Chang PL, Chen CL, Weng SC, Tsui KH. 2022. Comparison of outcome and quality of life between thulium laser (Vela™ XL) enucleation of prostate and bipolar transurethral enucleation of the prostate (B-TUEP). *Therapeutics and Clinical Risk Management* 18, 145.

108. Ho CP, Tsui KH, Chen ST, Chang KS, Sung HC, Hsu SY, Lin YH, Feng TH, , **Juang HH***. 2022. The Upregulation of caffeic acid phenethyl ester on growth differentiation factor 15 inhibits transforming growth factor β /Smad signaling in bladder carcinoma cells. *Biomedicines* 10:1625
109. Tsao SH, Wang CH, **Juang HH**, Lin YH,, Yang PS, Chang PL, Chen CL, Hou CP. 2022. Surgery for Xanthogranulomatous Pyelonephritis: A Comparison of Midline Transperitoneal and Flank Retroperitoneal Laparotomy Approaches to Nephrectomy. *Journal of Clinical Medicine* 11, 4476
110. Sung HC, Chang KS, Chen ST, Hsu SY, Lin YH, HouCP, Feng TH, Tsui KH, **Juang HH***. 2022. Metallothionein 2A with antioxidant and antitumor activity is upregulated by caffeic acid phenethyl ester in human bladder carcinoma cells. *Antioxidants* 11:1509.